Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23552453 | 1.00 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL28854052 | 0.84 | KDM4E (0.56) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL25761663 | 0.84 | KDM4E (0.56) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1058214 | 0.84 | KDM4E (0.56) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1058215 | 0.84 | KDM4E (0.56) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL313185 | 0.83 | ACE (0.41) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL14763564 | 0.83 | ACE (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL14763562 | 0.83 | ACE (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL6552340 | 0.82 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7259700 | 0.82 | ACE (0.59) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203622-B2 | MASP isoforms as inhibitors of complement activation | OMEROS CORPORATION (US) | 2021-12-21 | — | — | US | claimed |
| EP-2688578-B1 | MIA (MELANOMA INHIBITORY ACTIVITY) INHIBITORS FOR PREVENTING AND CURING VITILIGO | BORDIGNON MATTEO (IT) | 2019-03-27 | — | — | EP | claimed |
| EP-2688578-A2 | MIA (MELANOMA INHIBITORY ACTIVITY) INHIBITORS FOR DETECTING, PREVENTING AND CURING VITILIGO | Bordignon, Matteo (IT) | 2014-01-29 | — | — | EP | claimed |
| US-20140004130-A1 | MIA (Melanoma Inhibitory Activity) Inhibitors for Detecting, Preventing and Curing Vitiligo | BORDIGNON MATTEO (IT) | 2014-01-02 | — | — | US | claimed |
| WO-2012127352-A2 | MIA (MELANOMA INHIBITORY ACTIVITY) INHIBITORS FOR DETECTING, PREVENTING AND CURING VITILIGO | BORDIGNON MATTEO (IT) | 2012-09-27 | — | — | WO | claimed |
| US-20120208774-A1 | METHOD FOR INHIBITING \"MELANOMA INHIBITORY ACTIVITY\" MIA | ANTISENSE PHARMA GMBH (DE) | 2012-08-16 | — | — | US | claimed |
| US-8148493-B2 | Method for inhibiting “melanoma inhibitory activity” MIA | ANTISENSE PHARMA GMBH (DE) | 2012-04-03 | — | — | US | claimed |
| US-20100273705-A1 | Method for inhibiting \"Melanoma Inhibitory Activity\" MIA | ANTISENSE PHARMA GMBH. | 2010-10-28 | — | — | US | claimed |
| US-20060128607-A1 | Method for inhibiting \"melanoma inhibitory activity\" mia | ANTISENSE PHARMA GMBH (DE) | 2006-06-15 | — | — | US | claimed |
| US-20260146104-A1 | ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-107513103-B | MASP isoforms as inhibitors of complement activation | OMEROS CORP. (US) | 2026-05-26 | — | — | CN | disclosed |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250376499-A1 | MODIFIED GIP PEPTIDE ANALOGUES | ANTAG THERAPEUTICS APS (DK) | 2025-12-11 | — | — | US | disclosed |
| US-20250346647-A2 | Optimized GIP Peptide Analogues | ANTAG THERAPEUTICS APS (DK) | 2025-11-13 | — | — | US | disclosed |
| WO-1998029419-A1 | CYANOPHOSPHORUS COMPOUNDS AND THEIR PREPARATION | MONSANTO COMPANY (US) | 1998-07-09 | — | — | WO | disclosed |
| WO-1998027210-A1 | COMPOSITIONS AND METHODS FOR STIMULATING PANCREATIC ISLET CELL REGENERATION | ZYMOGENETICS, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998016635-A1 | INSULIN HOMOLOGS | ZYMOGENETICS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016644-A1 | FIBROBLAST GROWTH FACTOR HOMOLOGS | ZYMOGENETICS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998005782-A1 | TESTIS-SPECIFIC INSULIN HOMOLOG POLYPEPTIDES | ZYMOGENETICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0299715-A2 | Process for preparing L-tryptophan | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376499-A1 | MODIFIED GIP PEPTIDE ANALOGUES | GIPR, GLP1R, GPR119 | KDM4E 4591/4885MAPT 4749/4885THRB 340/4885 |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | HBZ, HBB, HBG2 | KDM4E 799/4885MAPT 3133/4885THRB 1067/4885 |
| US-20260146104-A1 | ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF | MMP13, ADAMTS13, MMP9 | KDM4E 1238/4885MAPT 2100/4885THRB 3151/4885 |
| US-20250346647-A2 | Optimized GIP Peptide Analogues | GIPR, IAPP, GLP1R | KDM4E 4345/4885MAPT 4445/4885THRB 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.